統合失調症の疫学分析および予測、2021年～2031年

世界の主要7ヶ国市場では、12ヶ月間の統合失調症有病者総数は、2021年の512万1,015例から2031年には533万3,310例へと、年間成長率（AGR）0.41%で増加すると予測されています。2031年には、主要7ヶ国市場における12カ月間の統合失調症有病者数合計は米国が296万3,482人と最も多く、イタリアが22万9,556人と最も少なくなると予測されます。

当レポートでは、世界の主要7ヶ国における統合失調症市場について調査し、疾患の概要、年齢別、性別の12か月の総罹患率および診断済み症例件数などを提供しています。

目次

目次

第1章 統合失調症：エグゼクティブサマリー

第2章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界的および歴史的動向
• 主要7ヶ国の予測調査手法
• 統合失調症の疫学的予測（2021年～2031年）
  • 統合失調症の12か月の総罹患率
  • 統合失調症の12か月の診断済み症例件数
  • 統合失調症の12か月の診断済み有病率、年齢別
  • 統合失調症の12か月の診断済み症例件数、性別
• 討論
  • 疫学的予測の洞察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

• 参考文献
• 著者について
• お問合せ

List of Tables

List of Tables

• Table 1: Summary of newly added data types
• Table 2: Summary of updated data types
• Table 3: Risk factors and comorbid conditions associated with schizophrenia

List of Figures

List of Figures

• Figure 1: 7MM, 12-month total prevalent cases of schizophrenia, both sexes, N, ages ≥13 years, 2021 and 2031
• Figure 2: 7MM, 12-month diagnosed prevalent cases of schizophrenia, both sexes, N, ages ≥13 years, 2021 and 2031
• Figure 3: 7MM, 12-month total prevalence (%) of schizophrenia, both sexes, ages ≥13 years, 2021
• Figure 4: 7MM, 12-month diagnosed prevalence (%) of schizophrenia, men and women, ages ≥13 years, 2021
• Figure 5: 7MM, sources used to forecast the 12-month total prevalent cases of schizophrenia
• Figure 6: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of schizophrenia
• Figure 7: 7MM, 12-month total prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021
• Figure 8: 7MM, 12-month diagnosed prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021
• Figure 9: 7MM, 12-month diagnosed prevalent cases of schizophrenia by age, N, both sexes, 2021
• Figure 10: 7MM, 12-month diagnosed prevalent cases of schizophrenia by sex, N, ages ≥13 years, 2021

Schizophrenia is a chronic and debilitating mental illness, characterized by delusions, hallucinations, disorganized speech, trouble with thinking, and a lack of motivation. It is among the most disabling and economically catastrophic medical disorders. The disorder is characterized by the presence of both positive and negative symptoms. Positive symptoms tend to be psychotic and include hallucinations and delusions. Negative symptoms often occur years before the first psychotic event in affected individuals and can lead to the destruction of relationships, social exclusion, and withdrawal. Furthermore, individuals with schizophrenia can experience cognitive symptoms, such as difficulties with focusing and the ability to process and act on information. The diagnosis and treatment of persons with schizophrenia should contain recommendations on both the diagnostic work-up and the pharmacological, psychotherapeutic, and psychosocial treatment over their entire life span.

In the 7MM, 12-month total prevalent cases of schizophrenia are expected to increase from 5,121,015 cases in 2021 to 5,333,310 cases in 2031, at an annual growth rate (AGR) of 0.41%. In 2031, the US will have the highest number of 12-month total prevalent cases of schizophrenia in the 7MM, with 2,963,482 cases, whereas Italy will have the fewest 12-month total prevalent cases of schizophrenia with 229,556 cases.

In the 7MM, 12-month diagnosed prevalent cases of schizophrenia are expected to increase from 3,403,962 cases in 2021 to 3,492,498 cases in 2031, at an AGR of 0.26%. In 2031, the US will have the highest number of 12-month diagnosed prevalent cases of schizophrenia in the 7MM, with 1,959,920 cases, whereas Italy will have the fewest 12-month diagnosed prevalent cases of schizophrenia with 150,761 cases.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical trends for schizophrenia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides a 10-year epidemiological forecast for 12-month total prevalent cases and 12-month diagnosed prevalent cases of schizophrenia.
• The 12-month diagnosed prevalent cases of schizophrenia are further segmented by age (13-17 years, 18-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) in these markets.
• The schizophrenia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The schizophrenia epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
• Quantify patient populations in the global schizophrenia market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for schizophrenia therapeutics in each of the markets covered.
• Enable to understand the magnitude of 12-month diagnosed prevalence of schizophrenia.

Table of Contents

Table of Contents

1 Schizophrenia: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumptions and methods: 12-month total prevalent cases of schizophrenia
  • 2.4.4 Forecast assumptions and methods: 12-month diagnosed prevalent cases of schizophrenia
• 2.5 Epidemiological forecast for schizophrenia (2021-31)
  • 2.5.1 12-Month total prevalent cases of schizophrenia
  • 2.5.2 12-Month diagnosed prevalent cases of schizophrenia
  • 2.5.3 Age-specific 12-month diagnosed prevalent cases of schizophrenia
  • 2.5.4 Sex-specific 12-month diagnosed prevalent cases of schizophrenia
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Global Director of Therapy Analysis and Epidemiology
  • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us